Form 4: Janux Therapeutics CEO David Campbell Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Janux Therapeutics CEO David Campbell sold a portion of his common stock holdings on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On October 28, 2024, David Alan Campbell, the President and CEO of Janux Therapeutics, sold shares of the company's common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on June 21, 2024.
- Two transactions occurred: one involving the sale of 13,897 shares at a weighted average price of $53.2237, and another involving the sale of 11,103 shares at a weighted average price of $53.9412.
- Following these transactions, Campbell directly owns 282,054 shares of Janux Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan, which doesn't inherently indicate positive or negative sentiment.
Industry Context
Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-scheduled. However, investors often monitor insider transactions for signals about a company's prospects.
Stakeholder Impact
- Shareholders may react to the news of the CEO's stock sale, although the existence of a 10b5-1 plan may mitigate concerns.
Key Dates
| Date | Description |
|---|---|
| June 21, 2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| October 28, 2024 | Date of the stock sale transactions |
| October 30, 2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.